TLR7/8 antagonist 1

• UNSPSC Description:

  TLR7/8 Antagonist 1 (Compound 16c) is the potent antagonist of TLR7/8 with IC50s of 3.91 and 2.19 μM, respectively. TLR7/8 Antagonist 1 is an imidazoquinoline derivative compound. Toll-like receptors (TLRs) 7 and 8 are key targets in the development of immunomodulatory drugs for researching infectious disease, cancer, and autoimmune disorders[1].

• Target Antigen:

  Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/tlr7-8-antagonist-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC(C1=CC2=NC(N)=C3N=C(N(C3=C2C=C1)CC4=CC=C(CN)C=C4)CC(C)C)=O

• Molecular Weight:

  417.50

• References & Citations:

  [1]Yang M, et al. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs. Bioorg Med Chem Lett. 2022;59:128548.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2901020-63-9